AngioTarget         Angiostatic strategies for cancer therapy                  

 

 

Home

 

The Company

 

Technology

 

Publications

 

News

 

Links

 

Contact

 

 

 

 

 

 

 

 

 

 

 

 

 

Publications

 


Wentink MQ, Hackeng TM, Tabruyn SP, Puijk WC, Schwamborn K, Altschuh D, Meloen RH, Schuurman T, Griffioen AW, Timmerman P Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity. Proc.Natl.Acad.Sci USA, In press, 2016

Huijbers EJ, van Beijnum JR, Thijssen VL, Sabrkhany S, Nowak-Sliwinska P, Griffioen AW. Role of the tumor stroma in resistance to anti-angiogenic therapy. Drug Resist Updat. 25:26-37, 2016.

Wentink MQ, Huijbers EJM, De Gruijl TD, Verheul HMW, Olsson AK, Griffioen AW. Vaccination approach to angiostatic treatment of cancer. BBA Cancer 1855:155-71, 2015.


Van Beijnum JR, Dings RPM, Zwaans B, Van der Linden E, Ramaekers FCS, Mayo KH and Griffioen AW. Gene expression of tumor angiogenesis dissected; specific targeting of colon cancer angiogenic vasculature. Blood, 108:2339-2348, 2006.


Dirkx AEM, oude-Egbrink MG, Castermans K, Thijssen VLJL, Van der Schaft DWJ, Dings RPM, Kwee L, Mayo KH, Wagstaff J, Bouma-Ter Steege JCA, Griffioen AW. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 20:621-30, 2006.

 

Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases and chronic inflammation. Pharmacol.Rev. 52: 237-268, 2000

                                 

    

 

 

   

© AngioVacs BV